Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China
As China is one of high MDR-TB burden countries, it is important to determine the drug resistant pattern and clinical characteristics of multidrug resistant tuberculosis (MDR-TB). We conducted a comprehensive and nationwide study on MDR-TB in 17 provinces for the period from June 2009 to June 2015,...
Gespeichert in:
| Veröffentlicht in: | PloS one 2019-11, Vol.14 (11), p.e0225361-e0225361 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0225361 |
|---|---|
| container_issue | 11 |
| container_start_page | e0225361 |
| container_title | PloS one |
| container_volume | 14 |
| creator | Lu, Zhenhui Jiang, Wenhan Zhang, Jing Lynn, Henry S Chen, Yue Zhang, Shaoyan Ma, Zifeng Geng, Peihua Guo, Xiaoyan Zhang, Huiyong Zhang, Zhijie |
| description | As China is one of high MDR-TB burden countries, it is important to determine the drug resistant pattern and clinical characteristics of multidrug resistant tuberculosis (MDR-TB). We conducted a comprehensive and nationwide study on MDR-TB in 17 provinces for the period from June 2009 to June 2015, and a total of 1154 cases of MDR-TB were finally investigated. The study sought to assess the clinical features and contrast drug susceptibility profiles of MDR-TB patients in China. Cavitary disease, young age, and long duration of TB disease among MDR-TB patients were important predictors. A high resistance proportion of first-line drugs was observed in Beijing, Shanghai and Tianjin. Resistant proportions of second-line anti-TB drugs in western region for amikacin, aminosalicylic acid, and levofloxacin were higher than eastern and central regions. High levels of drug resistance were seen in earlier cases (before 2011) and outpatients. We found high levels of resistance to 1st- and 2nd-line drugs in all settings, with considerable variabilities in terms of different Directly Observed Treatment Short Course (DOTS) programme, level of economic development(eastern, central and western regions) and patient source (inpatients and outpatients). Timely drug susceptibility testing (DST) and effective management are necessary to ensure an early detection of MDR-TB and its proper treatment. |
| doi_str_mv | 10.1371/journal.pone.0225361 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2316785973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A606436382</galeid><doaj_id>oai_doaj_org_article_2840d0fb45ec40bdaf68c68fa5048c1e</doaj_id><sourcerecordid>A606436382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-6cf1e7636a0cd158e82c9498b6ffd87a8c72ab2c9d035d6e86d63d8f02f721b13</originalsourceid><addsrcrecordid>eNqNk9uK2zAQhk1p6W7TvkFpDYXSXiTVwZblm8KSngILCz3dClkHR0GxvJIcum9fJXGWuOxF0YXF-Pv_0Yw0WfYSggXEFfywcYPvuF30rlMLgFCJCXyUXcIaozlBAD8-219kz0LYAFBiSsjT7ALDqoS4BpfZ7pMf2tyrYELknVA572SueiPV1jjr2rtcrLnnIiqfCCNC7nS-HWw0MgnnJ2HM49AoLwbrUiDveTSqiyE3XQ6rvPduZ5L5Qbxcm44_z55oboN6MX5n2a8vn38uv82vb76ullfXc0FqFOdEaKgqggkHQsKSKopEXdS0IVpLWnEqKsSbFJMAl5IoSiTBkmqAdIVgA_Ese3307dPB2NiywBCGpKJlXeFErI6EdHzDem-23N8xxw07BJxvGfepcKsYogWQQDdFqUQBGsk1oYJQzUtQUAFV8vo4ZhuarZIitcBzOzGd_unMmrVuxwitCkCKZPBuNPDudlAhsq0JQlnLO-WGw7mrktZ1ushZ9uYf9OHqRqrlqQDTaZfyir0puyL7jARTlKjFA1Ra-1cg0vvSJsUngvcTQWKi-hNbPoTAVj--_z9783vKvj1j14rbuA7ODtG4LkzB4ggK70LwSt83GQK2H49TN9h-PNg4Hkn26vyC7kWnecB_AT95DLk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2316785973</pqid></control><display><type>article</type><title>Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Lu, Zhenhui ; Jiang, Wenhan ; Zhang, Jing ; Lynn, Henry S ; Chen, Yue ; Zhang, Shaoyan ; Ma, Zifeng ; Geng, Peihua ; Guo, Xiaoyan ; Zhang, Huiyong ; Zhang, Zhijie</creator><creatorcontrib>Lu, Zhenhui ; Jiang, Wenhan ; Zhang, Jing ; Lynn, Henry S ; Chen, Yue ; Zhang, Shaoyan ; Ma, Zifeng ; Geng, Peihua ; Guo, Xiaoyan ; Zhang, Huiyong ; Zhang, Zhijie</creatorcontrib><description>As China is one of high MDR-TB burden countries, it is important to determine the drug resistant pattern and clinical characteristics of multidrug resistant tuberculosis (MDR-TB). We conducted a comprehensive and nationwide study on MDR-TB in 17 provinces for the period from June 2009 to June 2015, and a total of 1154 cases of MDR-TB were finally investigated. The study sought to assess the clinical features and contrast drug susceptibility profiles of MDR-TB patients in China. Cavitary disease, young age, and long duration of TB disease among MDR-TB patients were important predictors. A high resistance proportion of first-line drugs was observed in Beijing, Shanghai and Tianjin. Resistant proportions of second-line anti-TB drugs in western region for amikacin, aminosalicylic acid, and levofloxacin were higher than eastern and central regions. High levels of drug resistance were seen in earlier cases (before 2011) and outpatients. We found high levels of resistance to 1st- and 2nd-line drugs in all settings, with considerable variabilities in terms of different Directly Observed Treatment Short Course (DOTS) programme, level of economic development(eastern, central and western regions) and patient source (inpatients and outpatients). Timely drug susceptibility testing (DST) and effective management are necessary to ensure an early detection of MDR-TB and its proper treatment.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0225361</identifier><identifier>PMID: 31751390</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Aged ; Amikacin ; Aminosalicylic acids ; Antibacterial agents ; Antitubercular agents ; Antitubercular Agents - pharmacology ; Antitubercular Agents - therapeutic use ; Biology and Life Sciences ; China - epidemiology ; Chinese medicine ; Drug resistance ; Drug Resistance, Multiple, Bacterial ; Drugs ; Economic development ; Epidemiology ; Female ; Health care ; High resistance ; Hospitals ; Humans ; Infectious diseases ; Levels ; Levofloxacin ; Lung diseases ; Male ; Medical diagnosis ; Medicine and Health Sciences ; Microbial drug resistance ; Middle Aged ; Multidrug resistance ; Multidrug resistant organisms ; Mycobacterium tuberculosis - drug effects ; Patients ; People and Places ; Prevalence ; Preventive medicine ; Provinces ; Public health ; Risk Factors ; Socioeconomic Factors ; Sputum - microbiology ; Studies ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - epidemiology ; Young Adult</subject><ispartof>PloS one, 2019-11, Vol.14 (11), p.e0225361-e0225361</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><rights>2019 Lu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Lu et al 2019 Lu et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-6cf1e7636a0cd158e82c9498b6ffd87a8c72ab2c9d035d6e86d63d8f02f721b13</citedby><cites>FETCH-LOGICAL-c692t-6cf1e7636a0cd158e82c9498b6ffd87a8c72ab2c9d035d6e86d63d8f02f721b13</cites><orcidid>0000-0002-1276-787X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874064/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874064/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31751390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Zhenhui</creatorcontrib><creatorcontrib>Jiang, Wenhan</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Lynn, Henry S</creatorcontrib><creatorcontrib>Chen, Yue</creatorcontrib><creatorcontrib>Zhang, Shaoyan</creatorcontrib><creatorcontrib>Ma, Zifeng</creatorcontrib><creatorcontrib>Geng, Peihua</creatorcontrib><creatorcontrib>Guo, Xiaoyan</creatorcontrib><creatorcontrib>Zhang, Huiyong</creatorcontrib><creatorcontrib>Zhang, Zhijie</creatorcontrib><title>Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>As China is one of high MDR-TB burden countries, it is important to determine the drug resistant pattern and clinical characteristics of multidrug resistant tuberculosis (MDR-TB). We conducted a comprehensive and nationwide study on MDR-TB in 17 provinces for the period from June 2009 to June 2015, and a total of 1154 cases of MDR-TB were finally investigated. The study sought to assess the clinical features and contrast drug susceptibility profiles of MDR-TB patients in China. Cavitary disease, young age, and long duration of TB disease among MDR-TB patients were important predictors. A high resistance proportion of first-line drugs was observed in Beijing, Shanghai and Tianjin. Resistant proportions of second-line anti-TB drugs in western region for amikacin, aminosalicylic acid, and levofloxacin were higher than eastern and central regions. High levels of drug resistance were seen in earlier cases (before 2011) and outpatients. We found high levels of resistance to 1st- and 2nd-line drugs in all settings, with considerable variabilities in terms of different Directly Observed Treatment Short Course (DOTS) programme, level of economic development(eastern, central and western regions) and patient source (inpatients and outpatients). Timely drug susceptibility testing (DST) and effective management are necessary to ensure an early detection of MDR-TB and its proper treatment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Amikacin</subject><subject>Aminosalicylic acids</subject><subject>Antibacterial agents</subject><subject>Antitubercular agents</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Biology and Life Sciences</subject><subject>China - epidemiology</subject><subject>Chinese medicine</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drugs</subject><subject>Economic development</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Health care</subject><subject>High resistance</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Levels</subject><subject>Levofloxacin</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medicine and Health Sciences</subject><subject>Microbial drug resistance</subject><subject>Middle Aged</subject><subject>Multidrug resistance</subject><subject>Multidrug resistant organisms</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Patients</subject><subject>People and Places</subject><subject>Prevalence</subject><subject>Preventive medicine</subject><subject>Provinces</subject><subject>Public health</subject><subject>Risk Factors</subject><subject>Socioeconomic Factors</subject><subject>Sputum - microbiology</subject><subject>Studies</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - epidemiology</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9uK2zAQhk1p6W7TvkFpDYXSXiTVwZblm8KSngILCz3dClkHR0GxvJIcum9fJXGWuOxF0YXF-Pv_0Yw0WfYSggXEFfywcYPvuF30rlMLgFCJCXyUXcIaozlBAD8-219kz0LYAFBiSsjT7ALDqoS4BpfZ7pMf2tyrYELknVA572SueiPV1jjr2rtcrLnnIiqfCCNC7nS-HWw0MgnnJ2HM49AoLwbrUiDveTSqiyE3XQ6rvPduZ5L5Qbxcm44_z55oboN6MX5n2a8vn38uv82vb76ullfXc0FqFOdEaKgqggkHQsKSKopEXdS0IVpLWnEqKsSbFJMAl5IoSiTBkmqAdIVgA_Ese3307dPB2NiywBCGpKJlXeFErI6EdHzDem-23N8xxw07BJxvGfepcKsYogWQQDdFqUQBGsk1oYJQzUtQUAFV8vo4ZhuarZIitcBzOzGd_unMmrVuxwitCkCKZPBuNPDudlAhsq0JQlnLO-WGw7mrktZ1ushZ9uYf9OHqRqrlqQDTaZfyir0puyL7jARTlKjFA1Ra-1cg0vvSJsUngvcTQWKi-hNbPoTAVj--_z9783vKvj1j14rbuA7ODtG4LkzB4ggK70LwSt83GQK2H49TN9h-PNg4Hkn26vyC7kWnecB_AT95DLk</recordid><startdate>20191121</startdate><enddate>20191121</enddate><creator>Lu, Zhenhui</creator><creator>Jiang, Wenhan</creator><creator>Zhang, Jing</creator><creator>Lynn, Henry S</creator><creator>Chen, Yue</creator><creator>Zhang, Shaoyan</creator><creator>Ma, Zifeng</creator><creator>Geng, Peihua</creator><creator>Guo, Xiaoyan</creator><creator>Zhang, Huiyong</creator><creator>Zhang, Zhijie</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1276-787X</orcidid></search><sort><creationdate>20191121</creationdate><title>Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China</title><author>Lu, Zhenhui ; Jiang, Wenhan ; Zhang, Jing ; Lynn, Henry S ; Chen, Yue ; Zhang, Shaoyan ; Ma, Zifeng ; Geng, Peihua ; Guo, Xiaoyan ; Zhang, Huiyong ; Zhang, Zhijie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-6cf1e7636a0cd158e82c9498b6ffd87a8c72ab2c9d035d6e86d63d8f02f721b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Amikacin</topic><topic>Aminosalicylic acids</topic><topic>Antibacterial agents</topic><topic>Antitubercular agents</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Biology and Life Sciences</topic><topic>China - epidemiology</topic><topic>Chinese medicine</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drugs</topic><topic>Economic development</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Health care</topic><topic>High resistance</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Levels</topic><topic>Levofloxacin</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medicine and Health Sciences</topic><topic>Microbial drug resistance</topic><topic>Middle Aged</topic><topic>Multidrug resistance</topic><topic>Multidrug resistant organisms</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Patients</topic><topic>People and Places</topic><topic>Prevalence</topic><topic>Preventive medicine</topic><topic>Provinces</topic><topic>Public health</topic><topic>Risk Factors</topic><topic>Socioeconomic Factors</topic><topic>Sputum - microbiology</topic><topic>Studies</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Zhenhui</creatorcontrib><creatorcontrib>Jiang, Wenhan</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Lynn, Henry S</creatorcontrib><creatorcontrib>Chen, Yue</creatorcontrib><creatorcontrib>Zhang, Shaoyan</creatorcontrib><creatorcontrib>Ma, Zifeng</creatorcontrib><creatorcontrib>Geng, Peihua</creatorcontrib><creatorcontrib>Guo, Xiaoyan</creatorcontrib><creatorcontrib>Zhang, Huiyong</creatorcontrib><creatorcontrib>Zhang, Zhijie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Zhenhui</au><au>Jiang, Wenhan</au><au>Zhang, Jing</au><au>Lynn, Henry S</au><au>Chen, Yue</au><au>Zhang, Shaoyan</au><au>Ma, Zifeng</au><au>Geng, Peihua</au><au>Guo, Xiaoyan</au><au>Zhang, Huiyong</au><au>Zhang, Zhijie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2019-11-21</date><risdate>2019</risdate><volume>14</volume><issue>11</issue><spage>e0225361</spage><epage>e0225361</epage><pages>e0225361-e0225361</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>As China is one of high MDR-TB burden countries, it is important to determine the drug resistant pattern and clinical characteristics of multidrug resistant tuberculosis (MDR-TB). We conducted a comprehensive and nationwide study on MDR-TB in 17 provinces for the period from June 2009 to June 2015, and a total of 1154 cases of MDR-TB were finally investigated. The study sought to assess the clinical features and contrast drug susceptibility profiles of MDR-TB patients in China. Cavitary disease, young age, and long duration of TB disease among MDR-TB patients were important predictors. A high resistance proportion of first-line drugs was observed in Beijing, Shanghai and Tianjin. Resistant proportions of second-line anti-TB drugs in western region for amikacin, aminosalicylic acid, and levofloxacin were higher than eastern and central regions. High levels of drug resistance were seen in earlier cases (before 2011) and outpatients. We found high levels of resistance to 1st- and 2nd-line drugs in all settings, with considerable variabilities in terms of different Directly Observed Treatment Short Course (DOTS) programme, level of economic development(eastern, central and western regions) and patient source (inpatients and outpatients). Timely drug susceptibility testing (DST) and effective management are necessary to ensure an early detection of MDR-TB and its proper treatment.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31751390</pmid><doi>10.1371/journal.pone.0225361</doi><tpages>e0225361</tpages><orcidid>https://orcid.org/0000-0002-1276-787X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2019-11, Vol.14 (11), p.e0225361-e0225361 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2316785973 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adolescent Adult Aged Amikacin Aminosalicylic acids Antibacterial agents Antitubercular agents Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Biology and Life Sciences China - epidemiology Chinese medicine Drug resistance Drug Resistance, Multiple, Bacterial Drugs Economic development Epidemiology Female Health care High resistance Hospitals Humans Infectious diseases Levels Levofloxacin Lung diseases Male Medical diagnosis Medicine and Health Sciences Microbial drug resistance Middle Aged Multidrug resistance Multidrug resistant organisms Mycobacterium tuberculosis - drug effects Patients People and Places Prevalence Preventive medicine Provinces Public health Risk Factors Socioeconomic Factors Sputum - microbiology Studies Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology Young Adult |
| title | Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T05%3A00%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20resistance%20and%20epidemiology%20characteristics%20of%20multidrug-resistant%20tuberculosis%20patients%20in%2017%20provinces%20of%20China&rft.jtitle=PloS%20one&rft.au=Lu,%20Zhenhui&rft.date=2019-11-21&rft.volume=14&rft.issue=11&rft.spage=e0225361&rft.epage=e0225361&rft.pages=e0225361-e0225361&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0225361&rft_dat=%3Cgale_plos_%3EA606436382%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2316785973&rft_id=info:pmid/31751390&rft_galeid=A606436382&rft_doaj_id=oai_doaj_org_article_2840d0fb45ec40bdaf68c68fa5048c1e&rfr_iscdi=true |